...
首页> 外文期刊>International journal of antimicrobial agents >In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus
【24h】

In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus

机译:利奈唑胺联合庆大霉素在体内治疗耐甲氧西林金黄色葡萄球菌引起的实验性心内膜炎的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Indifference or even antagonism has mainly been reported with combinations including linezolid. The presence of in vitro antagonism is not always correlated with in vivo failure. The purpose of this study was to evaluate the in vivo activity of linezolid combined with gentamicin using a methicillin-resistant Staphylococcus aureus (MRSA) endocarditis experimental model. A human-like pharmacokinetic simulation was used for linezolid and gentamicin to improve the extrapolation of the results to human therapy. Contrary to the antagonism previously described in vitro, linezolid combined with gentamicin exhibited bactericidal activity on the two strains with a decrease of at least 4 log(10) cfu/g of vegetation compared with controls. These data suggest that linezolid plus gentamicin could be an appropriate combination for the treatment of severe MRSA infections. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
机译:对于包括利奈唑胺的组合,主要有冷漠甚至拮抗作用的报道。体外拮抗作用的存在并不总是与体内衰竭有关。本研究的目的是使用耐甲氧西林的金黄色葡萄球菌(MRSA)心内膜炎实验模型评估利奈唑胺联合庆大霉素的体内活性。对利奈唑胺和庆大霉素使用了类似于人的药代动力学模拟,以改善将结果推广至人用疗法的情况。与先前在体外描述的拮抗作用相反,利奈唑胺与庆大霉素的结合对两种菌株表现出杀菌活性,与对照相比至少减少了4 log(10)cfu / g的植被。这些数据表明,利奈唑胺加庆大霉素可能是治疗严重MRSA感染的适当组合。 (C)2004年Elsevier B.V.和国际化学疗法学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号